Symbols / PLRX
PLRX Chart
About
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 77.73M |
| Enterprise Value | -103.90M | Income | -175.50M | Sales | — |
| Book/sh | 3.26 | Cash/sh | 3.94 | Dividend Yield | — |
| Payout | 0.00% | Employees | 171 | IPO | — |
| P/E | — | Forward P/E | -0.68 | PEG | — |
| P/S | — | P/B | 0.39 | P/C | — |
| EV/EBITDA | 0.55 | EV/Sales | — | Quick Ratio | 13.77 |
| Current Ratio | 13.94 | Debt/Eq | 29.88 | LT Debt/Eq | — |
| EPS (ttm) | -2.86 | EPS next Y | -1.86 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-09 | ROA | -32.87% |
| ROE | -64.27% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 61.45M |
| Shs Float | 59.76M | Short Float | 6.97% | Short Ratio | 4.05 |
| Short Interest | — | 52W High | 3.46 | 52W Low | 1.09 |
| Beta | 1.35 | Avg Volume | 1.26M | Volume | 363.76K |
| Target Price | $3.25 | Recom | Hold | Prev Close | $1.27 |
| Price | $1.26 | Change | -0.39% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.25
Mean price target
2. Current target
$1.27
Latest analyst target
3. DCF / Fair value
$-32.48
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.27
Low
$2.00
High
$4.00
Mean
$3.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-07 | main | RBC Capital | Sector Perform → Sector Perform | $2 |
| 2025-10-10 | down | JP Morgan | Neutral → Underweight | — |
| 2025-08-08 | main | Piper Sandler | Overweight → Overweight | $4 |
| 2025-03-18 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-03-04 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-03-04 | main | Citigroup | Neutral → Neutral | $2 |
| 2025-03-04 | main | RBC Capital | Sector Perform → Sector Perform | $3 |
| 2025-03-04 | main | Wells Fargo | Equal-Weight → Equal-Weight | $3 |
| 2025-03-04 | down | Needham | Buy → Hold | $10 |
| 2025-03-03 | down | Leerink Partners | Outperform → Market Perform | $2 |
| 2025-02-14 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-14 | reit | Needham | Buy → Buy | $10 |
| 2025-02-10 | down | JP Morgan | Overweight → Neutral | — |
| 2025-02-10 | down | RBC Capital | Outperform → Sector Perform | $4 |
| 2025-02-10 | down | Canaccord Genuity | Buy → Hold | $4 |
| 2025-02-10 | down | Wells Fargo | Overweight → Equal-Weight | $4 |
| 2025-02-10 | down | Citigroup | Buy → Neutral | $4 |
| 2025-02-10 | main | Needham | Buy → Buy | $10 |
| 2025-02-10 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $38 |
- Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration - Seeking Alpha ue, 24 Feb 2026 06
- Pliant Therapeutics (Nasdaq: PLRX) reports interim PLN-101095 data with 1 CR, 3 PRs - Stock Titan hu, 04 Dec 2025 08
- Insider Sale: Chief Financial Officer of $PLRX Sells 24,002 Shares - Quiver Quantitative Fri, 23 Jan 2026 08
- PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know - Yahoo Finance hu, 27 Mar 2025 07
- Jobs Data: Is BROG part of any major index - 2025 Earnings Surprises & Technical Analysis for Trade Confirmation - baoquankhu1.vn Wed, 25 Feb 2026 08
- Penny Stocks To Watch With Market Caps Under $700M - simplywall.st Mon, 08 Sep 2025 07
- Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire hu, 07 Aug 2025 07
- Pliant Therapeutics stock jumps on promising cancer drug trial results - Investing.com hu, 04 Dec 2025 08
- symbol__ Stock Quote Price and Forecast - CNN Mon, 25 Mar 2024 20
- Why PLRX stock is recommended by analysts - Weekly Profit Recap & Consistent Return Strategy Ideas - mfd.ru Fri, 20 Feb 2026 05
- Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference - GlobeNewswire Mon, 01 Dec 2025 08
- Pliant Therapeutics CHRO Cheung sells $9.6k in stock - Investing.com hu, 22 Jan 2026 08
- Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results - Yahoo Finance hu, 06 Nov 2025 08
- Allogene, Pliant down as J.P. Morgan cuts to Underweight on uncertain outlook - Seeking Alpha Fri, 10 Oct 2025 07
- Pliant Therapeutics Stock: An Activist On Deck (NASDAQ:PLRX) - Seeking Alpha hu, 03 Apr 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 89375 | 114400 | — | Sale at price 1.28 per share. | COULIE BERNARD J | Chief Executive Officer | — | 2026-01-20 00:00:00 | D |
| 1 | 24002 | 30723 | — | Sale at price 1.28 per share. | CUMMINGS KEITH LAMONT | Chief Financial Officer | — | 2026-01-20 00:00:00 | D |
| 2 | 7534 | 9644 | — | Sale at price 1.28 per share. | CHEUNG LILY | Officer | — | 2026-01-20 00:00:00 | D |
| 3 | 6917 | 8854 | — | Sale at price 1.28 per share. | KUO MINNIE | Chief Operating Officer | — | 2026-01-20 00:00:00 | D |
| 4 | 162500 | — | — | Stock Award(Grant) at price 0.00 per share. | COULIE BERNARD J | Chief Executive Officer | — | 2025-01-23 00:00:00 | D |
| 5 | 56650 | — | — | Stock Award(Grant) at price 0.00 per share. | CUMMINGS KEITH LAMONT | Chief Financial Officer | — | 2025-01-23 00:00:00 | D |
| 6 | 35000 | — | — | Stock Award(Grant) at price 0.00 per share. | OUIMETTE MICHAEL | General Counsel | — | 2025-01-23 00:00:00 | D |
| 7 | 25875 | — | — | Stock Award(Grant) at price 0.00 per share. | CHEUNG LILY | Officer | — | 2025-01-23 00:00:00 | D |
| 8 | 45650 | — | — | Stock Award(Grant) at price 0.00 per share. | LEFEBVRE ERIC | Officer | — | 2025-01-23 00:00:00 | D |
| 9 | 40150 | — | — | Stock Award(Grant) at price 0.00 per share. | HULL JOHANNES P. | Officer | — | 2025-01-23 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -205.16M | -158.23M | -120.71M | -95.73M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -210.30M | -161.34M | -123.32M | -97.26M |
| ReconciledDepreciation | 2.12M | 1.84M | 1.82M | 1.53M |
| EBITDA | -205.16M | -158.23M | -120.71M | -95.73M |
| EBIT | -207.28M | -160.07M | -122.53M | -97.26M |
| NetInterestIncome | 18.06M | 22.81M | 3.88M | 272.00K |
| InterestExpense | 3.02M | 1.27M | 791.00K | 0.00 |
| InterestIncome | 21.09M | 24.08M | 4.67M | 272.00K |
| NormalizedIncome | -210.30M | -161.34M | -123.32M | -97.26M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -210.30M | -161.34M | -123.32M | -97.26M |
| TotalExpenses | 228.37M | 185.72M | 136.88M | 105.11M |
| TotalOperatingIncomeAsReported | -228.37M | -184.15M | -127.20M | -97.53M |
| DilutedAverageShares | 60.54M | 58.72M | 42.02M | 35.85M |
| BasicAverageShares | 60.54M | 58.72M | 42.02M | 35.85M |
| DilutedEPS | -3.47 | -2.75 | -2.94 | -2.71 |
| BasicEPS | -3.47 | -2.75 | -2.94 | -2.71 |
| DilutedNIAvailtoComStockholders | -210.30M | -161.34M | -123.32M | -97.26M |
| NetIncomeCommonStockholders | -210.30M | -161.34M | -123.32M | -97.26M |
| NetIncome | -210.30M | -161.34M | -123.32M | -97.26M |
| NetIncomeIncludingNoncontrollingInterests | -210.30M | -161.34M | -123.32M | -97.26M |
| NetIncomeContinuousOperations | -210.30M | -161.34M | -123.32M | -97.26M |
| PretaxIncome | -210.30M | -161.34M | -123.32M | -97.26M |
| NetNonOperatingInterestIncomeExpense | 18.06M | 22.81M | 3.88M | 272.00K |
| TotalOtherFinanceCost | -272.00K | |||
| InterestExpenseNonOperating | 3.02M | 1.27M | 791.00K | 0.00 |
| InterestIncomeNonOperating | 21.09M | 24.08M | 4.67M | 272.00K |
| OperatingIncome | -228.37M | -184.15M | -127.20M | -97.53M |
| OperatingExpense | 228.37M | 185.72M | 136.88M | 105.11M |
| ResearchAndDevelopment | 169.31M | 127.80M | 96.94M | 77.55M |
| SellingGeneralAndAdministration | 59.05M | 57.93M | 39.95M | 27.56M |
| GeneralAndAdministrativeExpense | 59.05M | 57.93M | 39.95M | 27.56M |
| OtherGandA | 59.05M | 57.93M | 39.95M | 27.56M |
| TotalRevenue | 0.00 | 1.58M | 9.69M | 7.57M |
| OperatingRevenue | 0.00 | 1.58M | 9.69M | 7.57M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 60.86M | 59.92M | 48.94M | 36.08M |
| ShareIssued | 60.86M | 59.92M | 48.94M | 36.08M |
| TotalDebt | 60.19M | 11.37M | 15.81M | 7.19M |
| TangibleBookValue | 304.08M | 473.58M | 313.34M | 199.06M |
| InvestedCapital | 334.29M | 483.63M | 323.27M | 199.06M |
| WorkingCapital | 329.05M | 476.98M | 316.40M | 192.61M |
| NetTangibleAssets | 304.08M | 473.58M | 313.34M | 199.06M |
| CapitalLeaseObligations | 29.98M | 1.32M | 5.89M | 7.19M |
| CommonStockEquity | 304.08M | 473.58M | 313.34M | 199.06M |
| TotalCapitalization | 334.29M | 483.63M | 323.27M | 199.06M |
| TotalEquityGrossMinorityInterest | 304.08M | 473.58M | 313.34M | 199.06M |
| StockholdersEquity | 304.08M | 473.58M | 313.34M | 199.06M |
| GainsLossesNotAffectingRetainedEarnings | 321.00K | 345.00K | -1.96M | -201.00K |
| OtherEquityAdjustments | 321.00K | 345.00K | -1.96M | -201.00K |
| RetainedEarnings | -710.05M | -499.75M | -338.41M | -215.09M |
| AdditionalPaidInCapital | 1.01B | 972.97M | 653.71M | 414.35M |
| CapitalStock | 6.00K | 6.00K | 5.00K | 3.00K |
| CommonStock | 6.00K | 6.00K | 5.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 92.87M | 38.58M | 37.27M | 22.16M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 59.65M | 10.05M | 13.36M | 5.33M |
| NonCurrentDeferredLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 59.65M | 10.05M | 13.36M | 5.33M |
| LongTermCapitalLeaseObligation | 29.44M | 0.00 | 3.43M | 5.33M |
| LongTermDebt | 30.21M | 10.05M | 9.93M | |
| CurrentLiabilities | 33.22M | 28.52M | 23.91M | 16.83M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 542.00K | 1.32M | 2.46M | 1.87M |
| CurrentCapitalLeaseObligation | 542.00K | 1.32M | 2.46M | 1.87M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.15M | 9.04M | 7.20M | 5.22M |
| PayablesAndAccruedExpenses | 21.52M | 18.16M | 14.26M | 9.75M |
| CurrentAccruedExpenses | 15.56M | 13.63M | 12.68M | 6.78M |
| Payables | 5.96M | 4.53M | 1.58M | 2.97M |
| AccountsPayable | 5.96M | 4.53M | 1.58M | 2.97M |
| TotalAssets | 396.95M | 512.15M | 350.61M | 221.22M |
| TotalNonCurrentAssets | 34.69M | 6.65M | 10.30M | 11.77M |
| OtherNonCurrentAssets | 1.92M | 1.87M | 394.00K | 838.00K |
| NetPPE | 32.77M | 4.78M | 9.91M | 10.94M |
| AccumulatedDepreciation | -10.81M | -8.68M | -6.84M | -5.02M |
| GrossPPE | 43.58M | 13.46M | 16.75M | 15.96M |
| Leases | 2.12M | 1.66M | 1.65M | 1.62M |
| ConstructionInProgress | 346.00K | 52.00K | 66.00K | 38.00K |
| OtherProperties | 38.23M | 11.62M | 15.00M | 14.28M |
| MachineryFurnitureEquipment | 2.88M | 124.00K | 30.00K | 22.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 362.26M | 505.50M | 340.31M | 209.44M |
| OtherCurrentAssets | 163.00K | 1.27M | 173.00K | 156.00K |
| PrepaidAssets | 4.08M | 6.99M | 5.81M | 6.22M |
| Receivables | 2.30M | 3.00M | 3.14M | 2.47M |
| TaxesReceivable | 0.00 | 83.00K | 83.00K | |
| AccruedInterestReceivable | 2.30M | 3.00M | 1.08M | 385.00K |
| AccountsReceivable | 0.00 | 1.98M | 2.00M | |
| CashCashEquivalentsAndShortTermInvestments | 355.72M | 494.25M | 331.19M | 200.60M |
| OtherShortTermInvestments | 284.54M | 431.01M | 297.50M | 148.93M |
| CashAndCashEquivalents | 71.19M | 63.23M | 33.69M | 51.66M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -159.35M | -117.28M | -96.39M | -77.40M |
| IssuanceOfDebt | 19.91M | 0.00 | 9.85M | 0.00 |
| IssuanceOfCapitalStock | 3.21M | 275.25M | 217.56M | 2.98M |
| CapitalExpenditure | -3.85M | -921.00K | -1.76M | -1.95M |
| InterestPaidSupplementalData | 2.62M | 1.15M | 615.00K | 0.00 |
| EndCashPosition | 72.67M | 64.72M | 33.68M | 51.66M |
| BeginningCashPosition | 64.72M | 33.68M | 51.66M | 50.88M |
| ChangesInCash | 7.95M | 31.03M | -17.98M | 783.00K |
| FinancingCashFlow | 23.12M | 274.40M | 226.85M | 2.53M |
| CashFlowFromContinuingFinancingActivities | 23.12M | 274.40M | 226.85M | 2.53M |
| NetOtherFinancingCharges | -847.00K | -557.00K | -457.00K | |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 3.21M | 275.25M | 217.56M | 2.98M |
| CommonStockIssuance | 3.21M | 275.25M | 217.56M | 2.98M |
| NetIssuancePaymentsOfDebt | 19.91M | 0.00 | 9.85M | 0.00 |
| NetLongTermDebtIssuance | 19.91M | 0.00 | 9.85M | 0.00 |
| LongTermDebtIssuance | 19.91M | 0.00 | 9.85M | 0.00 |
| InvestingCashFlow | 140.34M | -127.01M | -150.20M | 73.70M |
| CashFlowFromContinuingInvestingActivities | 140.34M | -127.01M | -150.20M | 73.70M |
| NetInvestmentPurchaseAndSale | 144.19M | -126.09M | -148.44M | 75.65M |
| SaleOfInvestment | 355.47M | 456.98M | 177.27M | 295.54M |
| PurchaseOfInvestment | -211.28M | -583.07M | -325.72M | -219.89M |
| NetPPEPurchaseAndSale | -3.85M | -921.00K | -1.76M | -1.95M |
| PurchaseOfPPE | -3.85M | -921.00K | -1.76M | -1.95M |
| OperatingCashFlow | -155.50M | -116.36M | -94.63M | -75.44M |
| CashFlowFromContinuingOperatingActivities | -155.50M | -116.36M | -94.63M | -75.44M |
| ChangeInWorkingCapital | 9.09M | 1.25M | 4.22M | 6.92M |
| ChangeInOtherCurrentLiabilities | -820.00K | -2.75M | -2.26M | -1.75M |
| ChangeInOtherCurrentAssets | -43.00K | 0.00 | 201.00K | 70.00K |
| ChangeInPayablesAndAccruedExpense | 5.24M | 5.75M | 6.55M | 3.59M |
| ChangeInAccruedExpense | 3.81M | 2.78M | 7.90M | 2.69M |
| ChangeInPayable | 1.43M | 2.97M | -1.35M | 891.00K |
| ChangeInAccountPayable | 1.43M | 2.97M | -1.35M | 891.00K |
| ChangeInPrepaidAssets | 4.72M | -3.73M | -294.00K | -2.27M |
| ChangeInReceivables | 0.00 | 1.98M | 15.00K | 7.28M |
| ChangesInAccountReceivables | 0.00 | 1.98M | 15.00K | 7.28M |
| OtherNonCashItems | 3.45M | 2.39M | 1.86M | 1.67M |
| StockBasedCompensation | 37.63M | 44.48M | 22.60M | 10.44M |
| AmortizationOfSecurities | 2.51M | -4.99M | -1.81M | 1.26M |
| DepreciationAmortizationDepletion | 2.12M | 1.84M | 1.82M | 1.53M |
| DepreciationAndAmortization | 2.12M | 1.84M | 1.82M | 1.53M |
| Depreciation | 2.12M | 1.84M | 1.82M | 1.53M |
| NetIncomeFromContinuingOperations | -210.30M | -161.34M | -123.32M | -97.26M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PLRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|